Drug name - Vyndaqel

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8168663 FOLDRX PHARMS Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof
Dec, 2023

(1 year, 3 months from now)

US7214695 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Apr, 2024

(1 year, 8 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214696 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding Dec, 2023

(1 year, 3 months from now)

US8653119 FOLDRX PHARMS Methods for treating transthyretin amyloid diseases Jan, 2024

(1 year, 5 months from now)

Drugs and Companies using TAFAMIDIS MEGLUMINE ingredient

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG CAPSULE;ORAL Prescription